Breaking Finance News

Sangamo Therapeutics Inc (NASDAQ:SGMO) has been upgraded to Hold in a report by Zacks Investment Research today.

Yesterday Sangamo Therapeutics Inc (NASDAQ:SGMO) traded -4.76% lower at $7.85. Sangamo Therapeutics Inc’s 50-day average is $4.67 and its two hundred day average is $3.97. With the last close up 101.47% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. Trade Volume was up over the average, with 2,408,464 shares of SGMO changing hands over the typical 1,008,510

Zacks Investment Research has upgraded Sangamo Therapeutics Inc (NASDAQ:SGMO) to Hold in a report released on Tuesday May 16, 2017.

See Chart Below

Sangamo Therapeutics Inc (NASDAQ:SGMO)

Sangamo Therapeutics Inc has a 52 week low of $2.65 and a 52 week high of $8.60 The company’s market cap is currently $0.

General Information About Sangamo Therapeutics Inc (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.